These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 7225883

  • 1. Parkinson's disease: low density and presynaptic location of D3 dopamine receptors.
    Lee T, Seeman P, Hornykiewicz O, Bilbao J, Deck J, Tourtellotte WW.
    Brain Res; 1981 May 18; 212(2):494-8. PubMed ID: 7225883
    [No Abstract] [Full Text] [Related]

  • 2. Direct evidence for presynaptic and postsynaptic dopamine receptors in brain.
    Nagy JI, Lee T, Seeman P, Fibiger HC.
    Nature; 1978 Jul 20; 274(5668):278-81. PubMed ID: 683308
    [No Abstract] [Full Text] [Related]

  • 3. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
    Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y.
    Eur J Pharmacol; 1984 Mar 23; 99(2-3):167-75. PubMed ID: 6734727
    [Abstract] [Full Text] [Related]

  • 4. Function of sigma1 receptors in Parkinson's disease.
    Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, Oda K, Sasaki T, Sakayori O, Hamamoto M, Kobayashi S, Katayama Y.
    Acta Neurol Scand; 2005 Aug 23; 112(2):103-7. PubMed ID: 16008536
    [Abstract] [Full Text] [Related]

  • 5. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD, Rossor M, Spokes E, Iversen LL, Yamamura HI.
    Brain Res; 1979 Sep 14; 173(2):378-82. PubMed ID: 226215
    [No Abstract] [Full Text] [Related]

  • 6. Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: a quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390.
    Filloux FM, Wamsley JK, Dawson TM.
    Brain Res; 1987 Apr 07; 408(1-2):205-9. PubMed ID: 2954613
    [Abstract] [Full Text] [Related]

  • 7. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
    Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y.
    J Neurol Sci; 1988 Sep 07; 86(2-3):291-306. PubMed ID: 2975699
    [Abstract] [Full Text] [Related]

  • 8. Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.
    Quik M, Spokes EG, Mackay AV, Bannister R.
    J Neurol Sci; 1979 Nov 07; 43(3):429-37. PubMed ID: 521836
    [Abstract] [Full Text] [Related]

  • 9. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
    Guttman M, Seeman P.
    J Neural Transm; 1985 Nov 07; 64(2):93-103. PubMed ID: 2934514
    [Abstract] [Full Text] [Related]

  • 10. [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.
    Nishino N, Noguchi-Kuno SA, Sugiyama T, Tanaka C.
    Brain Res; 1986 Jul 02; 377(1):186-9. PubMed ID: 2942224
    [Abstract] [Full Text] [Related]

  • 11. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK.
    Brain; 1999 Aug 02; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [Abstract] [Full Text] [Related]

  • 12. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F, Fornai F, Blandini F.
    Funct Neurol; 2000 Aug 02; 15(4):269-76. PubMed ID: 11213530
    [No Abstract] [Full Text] [Related]

  • 13. Neurotransmitter receptor alterations in Parkinson's disease.
    Reisine TD, Fields JZ, Yamamura HI.
    Life Sci; 1977 Aug 01; 21(3):335-43. PubMed ID: 197361
    [No Abstract] [Full Text] [Related]

  • 14. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O.
    J Neurol Neurosurg Psychiatry; 1999 Dec 01; 67(6):737-41. PubMed ID: 10567489
    [Abstract] [Full Text] [Related]

  • 15. Proceedings: Para-o-methylation of dopamine in human brain.
    Ebinger G, Verheyden R.
    Acta Neurol Belg; 1975 Dec 01; 75(2):111. PubMed ID: 1155020
    [No Abstract] [Full Text] [Related]

  • 16. Dopamine receptors and transporters in Parkinson's disease and schizophrenia.
    Seeman P, Niznik HB.
    FASEB J; 1990 Jul 01; 4(10):2737-44. PubMed ID: 2197154
    [Abstract] [Full Text] [Related]

  • 17. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP, Rüther E.
    Nervenarzt; 1985 Feb 01; 56(2):69-81. PubMed ID: 3982566
    [No Abstract] [Full Text] [Related]

  • 18. Investigations concerning the cellular origin of dopamine receptors.
    Henn FA, Titeler M, Anderson DJ, May K.
    Life Sci; 1978 Aug 14; 23(6):617-21. PubMed ID: 692285
    [No Abstract] [Full Text] [Related]

  • 19. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.
    Brain; 2001 Apr 14; 124(Pt 4):784-92. PubMed ID: 11287377
    [Abstract] [Full Text] [Related]

  • 20. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.
    Ann Neurol; 1992 Feb 14; 31(2):184-92. PubMed ID: 1575457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.